GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • Amgen ends work on experimental psoriasis drug Friday, 22 May 2015 | 5:27 PM ET

    NEW YORK— Drugmakers Amgen and AstraZeneca said Friday that some patients who took an experimental psoriasis drug experienced suicidal thoughts or behavior, and Amgen said it is ending development of the drug. Amgen was in charge of studying brodalumab, a potential treatment for moderate to severe plaque psoriasis and two other inflammatory diseases,...

  • CHICAGO, May 22- Wal-Mart Stores Inc is pressing meat, seafood, dairy and egg suppliers to reduce the use of antibiotics, becoming the first large retailer to take such a public stand against the excessive use of drugs in raising farm animals. Wal-Mart, the country's biggest food retailer, is also telling suppliers not to raise animals in gestation crates or in...

  • Actavis hard switch   Friday, 22 May 2015 | 2:30 PM ET
    Actavis hard switch

    A federal appeals court has made a ruling on a top selling Alzheimer's drug that could make things difficult for drugmaker Actavis, reports CNBC's Meg Tirrell.

  • Wal-Mart urges meat suppliers to curb antibiotic use Friday, 22 May 2015 | 1:42 PM ET

    CHICAGO, May 22- Wal-Mart Stores Inc is pressing meat, seafood, dairy and egg suppliers to reduce the use of antibiotics, becoming the first large retailer to take a stand against the excessive use of drugs in raising farm animals. Wal-Mart, the country's biggest food retailer, is also telling suppliers not to raise animals in gestation crates or in other...

  • Actavis barred from pulling older Alzheimer's drug Friday, 22 May 2015 | 11:19 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Actavis cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier version, a federal appeals court ruled.

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday. The decision at the 2nd U.S. Circuit Court of Appeals is a win for New York State Attorney General Eric Schneiderman, who sued to block the switch, arguing that Actavis was...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. A three-judge panel at the 2nd U.S. Circuit Court of Appeals in New York upheld an order by U.S. District Robert Sweet in December requiring Actavis to keep the older drug, Namenda IR, on the...

  • *Seibu tumbles after Cerberus launched selldown. *Skylark dives after news Bain Capital to sell stake. TOKYO, May 22- Japan's Nikkei share average edged down on Friday morning, snapping a five-day winning streak as investors carefully await for the outcome of the Bank Of Japan's two-day policy meeting.

  • NEW YORK— Abbvie Inc. specified the stock and cash breakdown on Thursday of its previously announced $21 billion buyout of Pharmacyclics Inc.. The drugmaker said the mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie...

  • *Deal values Omnicare at $12.7 bln, including $2.3 B debt. May 21- Drugstore operator CVS Health Corp said Thursday it will spend $10.1 billion to buy Omnicare Inc, a company that supplies prescription medicines to nursing, assisted living and other healthcare facilities. They could renegotiate their supply contracts given the volume, "said FBR analyst Steven...

  • *Deal values Omnicare at $12.7 bln, including $2.3 bln debt. May 21- CVS Health Corp, the second-largest U.S. drugstore operator, said on Thursday it will buy pharmacy services provider Omnicare Inc for $10.1 billion to expand in the growing market serving the senior patient population. CVS offered $98 per Omnicare share, representing a premium of 4 percent to...

  • The hep C challenge   Wednesday, 20 May 2015 | 3:37 PM ET
    The hep C challenge

    Analysts tend to leave out Johnson & Johnson's hepatitis C drug out of the company's growth projections. Details, with NBC's Meg Tirrell.

  • How biotechs are affecting J&J's business   Wednesday, 20 May 2015 | 1:55 PM ET
    How biotechs are affecting J&J's business

    Michael Weinstein, JPM, managing director of healthcare, joins CNBC's Meg Tirrell to discuss biosimilar, the threat to big pharmaceuticals, and how Johnson & Johnson will be affected.

  • NEW YORK, May 20- A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia and Ukraine, challenges have been filed against Gilead's patents or patent applications, the New York- based...

  • Achillion sinks after partnering with Johnson & Johnson Wednesday, 20 May 2015 | 11:38 AM ET

    Investors started shedding Achillion shares early Wednesday, less than a day after the drugmaker announced a partnership with pharmaceutical giant Johnson& Johnson that snuffed out the prospect of a near-term acquisition. Achillion representatives said during a conference call that Johnson& Johnson will make a $225 million equity investment in their...

  • Johnson & Johnson's big plans   Wednesday, 20 May 2015 | 10:54 AM ET
    Johnson & Johnson's big plans

    CNBC's Meg Tirrell reports on Johnson & Johnson's plans for the years ahead.

  • J&J says will submit 10 medicines to regulators by 2019 Wednesday, 20 May 2015 | 9:20 AM ET

    NEW YORK, May 20- Drugmaker Johnson& Johnson said on Wednesday that it would submit 10 new medicines to regulators by 2019, forecasting that many of the drugs in its research and development pipeline will have more than $1 billion in peak annual sales. J&J said that it would submit experimental cancer drug daratumumab for use in double refractory multiple...

  • J&J: 10 new drugs by 2019, each with $1B potential Wednesday, 20 May 2015 | 9:11 AM ET
    Johnson & Johnson's Janssen Labs in La Jolla, California.

    "You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."

  • Johnson & Johnson makes what?!   Wednesday, 20 May 2015 | 8:30 AM ET
    Johnson & Johnson makes what?!

    The consumer products giant makes much more than baby powder. Some of what it sells may surprise you.